RWP
VRTX icon

RWA Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

RWA Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
2,714
+3
+0.1% +$1.33K 0.01% 313
2026
Q1 		$1.21M Buy
2,711
+74
+3% +$34.5K 0.01% 321
2025
Q4 		$1.2M Buy
2,637
+747
+40% +$322K 0.01% 329
2025
Q3 		$740K Sell
1,890
-453
-19% -$189K 0.01% 382
2025
Q2 		$1.04M Sell
2,343
-142
-6% -$65.4K 0.01% 323
2025
Q1 		$1.2M Sell
2,485
-1,098
-31% -$512K 0.02% 293
2024
Q4 		$1.44M Buy
3,583
+95
+3% +$44K 0.02% 278
2024
Q3 		$1.62M Buy
3,488
+65
+2% +$31.2K 0.02% 263
2024
Q2 		$1.6M Hold
3,423
– – 0.02% 253
2024
Q1 		$1.43M Sell
3,423
-195
-5% -$82.4K 0.02% 264
2023
Q4 		$1.47M Buy
3,618
+2,778
+331% +$1.03M 0.02% 253
2023
Q3 		$292K Buy
+840
New +$294K 0.01% 326
2018
Q3 		– Sell
-88
Closed -$15K – 686
2018
Q2 		$15K Buy
88
+35
+66% +$5.42K ﹤0.01% 570
2018
Q1 		$9K Buy
+53
New +$8.66K ﹤0.01% 459

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

RWA Wealth Partners's VRTX Position: Q2 2026 in Review

RWA Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 0.11% in Q2 2026, buying an estimated $1.33K and bringing the position to 2,714 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #313.

RWA Wealth Partners first reported a position in VRTX in Q1 2018 and has held it in 14 quarters since. The position peaked at $1.62M in Q3 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • RWA Wealth Partners held 2,714 shares of Vertex Pharmaceuticals worth $1.35M as of Q2 2026.
  • RWA Wealth Partners bought 3 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.33K.
  • Vertex Pharmaceuticals made up 0.01% of RWA Wealth Partners's portfolio in Q2 2026, its #313 holding.
  • RWA Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 14 quarters since.
  • RWA Wealth Partners's Vertex Pharmaceuticals position peaked at $1.62M in Q3 2024.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on RWA Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.